ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, BCR-ABL inhibitors have been shown to prevent the activation of both GCN2 and PERK, thereby inhibiting downstream ATF4 induction in chronic myeloid leukemia (177).